Results 71 to 80 of about 15,879 (168)

Prostate Cancer Development, Progression, and Therapy

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This review provides an integrated overview of prostate cancer development, progression, and therapy, spanning historical milestones, molecular mechanisms, advanced research models, and emerging therapeutic strategies. It highlights recent advances in precision diagnosis, lineage plasticity, therapy resistance, and next‐generation treatments for ...
Xin Jin, Zicheng Xiao, Zexian Ding, Wei Li, Ruijiang Zeng, Yujun Shuai, Weimin Ci, Dan Xia, Xu Zhang, Haojie Huang   +9 more
wiley   +1 more source

Oxysterols in Cancer: From Biosynthesis and Pathophysiology to Targeted Therapeutics

MedComm – Oncology, Volume 5, Issue 3, September 2026.
Mechanisms by which oxysterol targeting may enhance immunotherapy efficacy. This figure illustrates potential metabolic interventions that may improve antitumor immunity by modulating oxysterol related pathways. CH25H modulation may reduce 25‐HC accumulation, promote the conversion of cold tumors into hot tumors, and increase T cell infiltration and PD‐
Haili Shang, Yongsheng Li
wiley   +1 more source

Tributyltin Protumorigenic Effects Targeting Prostate Cancer Cell Metabolism, Proliferation, Migration, and Invasion

Environmental Toxicology, Volume 41, Issue 9, Page 709-729, September 2026.
ABSTRACT Prostate cancer (PCa) is an endocrine‐related cancer highly dependent on androgenic signaling. Beyond hormone dependence, extrinsic factors play a significant role in the risk of developing PCa, which raises concern about the influence of environmental compounds such as endocrine‐disrupting chemicals (EDCs). Tributyltin (TBT) is an EDC used in
Mariana Feijó, Luís P. Brás, Catarina M. D. Serra, Lara R. S. Fonseca, Sara Correia, Bruno J. Pereira, Ana P. Duarte, Henrique J. Cardoso, Cátia V. Vaz, Sílvia Socorro   +9 more
wiley   +1 more source

Intermediate clinical endpoints as surrogates for overall survival after salvage prostatectomy

BJU International, Volume 138, Issue 3, Page 430-437, September 2026.
Objectives To evaluate biochemical recurrence‐free survival (BRFS) and metastasis‐free survival (MFS) as potential intermediate clinical endpoints (ICEs) for overall survival (OS) in patients undergoing salvage radical prostatectomy (sRP). Patients and Methods Evaluable patients were selected from a retrospective dataset, resulting in a cohort of 879 ...
Navid Roessler, Zuzanna Nowicka, Marcin Miszczyk, Giorgio Calleris, Alessandro Dematteis, Malte W. Vetterlein, Simone Albisinni, Henk G Van Der Poel, Paul Cathcart, Giovanni E. Cacciamani, Inderbir S. Gill, Raj A. Persad, Steven Joniau, Rafael Sanchez‐Salas, Joseph A. Smith Jr, Robert Jeffrey Karnes, Mohamed E. Ahmed, Pawel Rajwa, Derya Tilki, Shahrokh F. Shariat, Paolo Gontero, Giancarlo Marra, on behalf of the Young Academic Urologists Prostate Cancer Working Party   +22 more
wiley   +1 more source

How low do you need to go? Association between various prostate‐specific antigen response measures and clinical outcomes in metastatic castration‐sensitive prostate cancer in the Veterans Health Administration data

Cancer, Volume 132, Issue 16, 15 August 2026.
In a retrospective analysis of Veterans Health Administration data for patients with metastatic castration‐sensitive prostate cancer (mCSPC), achieving a prostate‐specific antigen (PSA) of <0.2 ng/mL (whether or not a PSA decline of 90% was reached) within 9 months of initiating androgen deprivation therapy (ADT) ± other treatments was associated with ...
Stephen J. Freedland, Wei Gao, Maëlys Touya, Hongbo Yang, David Russell, Jingyi Chen, Grace Chen, Jasmina I. Ivanova   +7 more
wiley   +1 more source

A Non‐Canonical Core Transcriptional Regulatory Circuit Orchestrates Chromatin Reprogramming to Drive Osimertinib Resistance in Non‐Small Cell Lung Cancer

Advanced Science, Volume 13, Issue 46, 17 August 2026.
A non‐canonical core transcriptional regulatory circuit, composed of ID3, SMAD3, and NR2F2, drives Osimertinib resistance in non‐small cell lung cancer through super‐enhancer‐mediated activation of EPAS1, which couples neuroendocrine differentiation with ferroptosis evasion.
Aochu Liu, Zhenguo Liu, Lizhen Jiang, Andong Huang, Xinqing Lin, Xinyue Li, Bingyuan Liu, Shiwen Hu, Qiang Pan, Junjun Huang, Liyuan Yin, Liling Jiang, Wei Yi, Wenjun Mao, Yueyuan Zheng, Xianping Shi   +15 more
wiley   +1 more source

Applications of Artificial Intelligence in Cancer Diagnosis and Treatment

Cancer Medicine, Volume 15, Issue 8, August 2026.
This review explores how AI and multimodal data fusion transform oncology through enhanced screening, precision diagnosis, and personalized therapy. By dissecting core challenges—including data bias and explainability—it provides a strategic framework for the digital transformation and ethical implementation of AI in clinical cancer care.
Yifeng Xie, Zixuan Wang, Zhiwen Zeng, Tongyao Xin, Shaofei Yuan, Feiwei Qin, Zhonglin Chen   +6 more
wiley   +1 more source

The Local Effects of Systemic Therapies in Urological Oncology: A Systematic Review

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Background Systemic therapies can impact local disease progression in genitourinary malignancies, potentially reducing the necessity for extensive surgery. Understanding these effects is crucial for optimizing treatment approaches in urologic oncology.
Sharon Nordheimer, Ofer N. Gofrit
wiley   +1 more source

Vobramitamab duocarmazine, an anti–B7‐H3 antibody–drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansion

Cancer, Volume 132, Issue 15, 1 August 2026.
Abstract Background Vobramitamab duocarmazine is an investigational antibody–drug conjugate (ADC) targeting B7 homolog 3 (B7‐H3) with a cytotoxic duocarmycin‐based DNA‐alkylating payload. This study evaluated its safety and antitumor activity in advanced solid tumors.
Eugene Shenderov, Manish R. Sharma, Elena Garralda, John Powderly, Iwona Ługowska, Alexander Spira, Marc Cucurull Salamero, Sekwon Jang, Rasha Cosman, John Shen, Wen Xu, Piotr J. Wysocki, Rodryg Ramlau, Emmanuel S. Antonarakis, Andrew J. Weickhardt, Jakub Żołnierek, Emiliano Calvo, Enxu Zhao, Chet Bohac, Ashley Ward, Girish Mallesara   +20 more
wiley   +1 more source

ROS‐ATM‐CBP axis‐mediated PARP1 lactylation aggravates doxorubicin‐induced cardiotoxicity

Clinical and Translational Medicine, Volume 16, Issue 8, August 2026.
ROS function as signalling molecules to promote CBP‐mediated PARP1 lactylation in an ATM dependent manner, which induces PARP1 PARylation and ultimate cell apoptosis. CBP and SIRT1 as specific lactyltransferase and delactylase of PARP1. Lactylation of PARP1 depends on the LDHA activity and lactate production.
Wenbin Wang, Yingxian Sun
wiley   +1 more source